The obesity-drug race has been an arms race of stacked mechanisms: GLP-1, then GLP-1 plus GIP, then GLP-1 plus GIP plus glucagon. At the American Diabetes Association 2026 Scientific Sessions in New Orleans (June 5–8), Roche and Zealand Pharma made the opposite argument — that you can get clean, meaningful weight loss from a single hormone pathway and barely upset anyone's stomach.
That drug is petrelintide, a once-weekly amylin analog. The Phase 2 ZUPREME-1 readout showed 10.7% mean weight loss at 42 weeks — and a gastrointestinal side-effect profile that looked close to placebo. That tolerability number, not the weight-loss number, is the headline.
Here is what happened and what it means.
What ZUPREME-1 Showed
ZUPREME-1 was a 42-week, dose-finding Phase 2 trial in 493 adults with overweight or obesity (mean BMI 36.7 kg/m², 53% female), run across sites in the US, Poland, and Romania with a 5:1 randomization to petrelintide or placebo. Five once-weekly subcutaneous doses were tested. The data were first reported as topline in March 2026 and presented in detail at ADA 2026 on June 5.
Efficacy. The highest-performing arm reached 10.7% mean body weight reduction at week 42, versus 1.7% on placebo (p<0.001). All five dose arms hit statistically significant weight loss versus placebo by week 28, and that separation was sustained through week 42. Between 88% and 98% of participants successfully escalated to their target maintenance dose — a sign the titration schedule was manageable.
Tolerability — the real story. Amylin slows gastric emptying and signals satiety to the hindbrain, mechanisms that overlap GLP-1 enough that nausea and vomiting were expected. They mostly didn't show up:
- Nausea: 19.6% (petrelintide) vs 6.2% (placebo)
- Vomiting: 3.0% (petrelintide) vs 6.2% (placebo) — lower than placebo
- More than 75% of all GI events were mild
- Only 1.5% of participants discontinued because of GI adverse events
For context, GLP-1 drugs routinely produce nausea in 40–70% of patients during titration. A weight-loss agent that gets to double digits with a near-placebo GI profile is a genuinely different product.
Cardiometabolic. Waist circumference dropped 7.9–10.8 cm (vs 4.3 cm placebo), high-sensitivity CRP fell 17–41% (vs 6%), and triglycerides dropped 12–21% (vs 9%).
Sources: Zealand Pharma ZUPREME-1 ADA 2026 release (June 5, 2026); Roche Phase 2 topline release (March 5, 2026). Full ZUPREME-1 manuscript publication is expected later in 2026.
What This Means for You
If you follow the obesity-peptide space, petrelintide matters for two practical reasons.
First, it validates the amylin class as a tolerability play. The reason this class is interesting isn't that 10.7% beats semaglutide — it doesn't (semaglutide hits ~15% in STEP 1). It's that 10.7% comes without the nausea wall that drives a large share of GLP-1 dropouts. For people who can't tolerate semaglutide or tirzepatide, an amylin agonist is the most promising alternative mechanism in development. Roche and Zealand formally endorsed Phase 3 advancement in April 2026, with trials starting in the second half of this year.
Second, the only buyable amylin analog today is cagrilintide. Petrelintide itself is locked inside Roche's clinical program — research vendors do not stock it, and anything sold under that name should be treated as suspect. Cagrilintide is the closest accessible proxy for the amylin mechanism, with established research-vendor availability and COA documentation. Its Phase 2 monotherapy data (~10% over 26 weeks) is in the same neighborhood as petrelintide's, and it's the amylin half of CagriSema.
If you want the GLP-1 mechanisms that are actually available right now, retatrutide, tirzepatide, and semaglutide remain the most accessible options from research vendors. Compare COA-verified pricing on the best cagrilintide vendors, best retatrutide vendors, and best tirzepatide vendors pages, or browse current discount codes across the obesity-peptide category on the deals page.
